2022年3月22日

荷蘭埃因霍溫InnoSIGN利用其專有的數據庫超過100000通路活動概要藥物開發和診斷預測病人對靶向治療收益支持更多的臨床驗證和美國市場推出威爾明頓,德爾。2022年3月22日,荷蘭埃因霍溫(全球通訊社)——InnoSIGN,精密醫學公司今天宣布,它提出了一個係列8美元融資。所得將用來資助從皇家飛利浦公司形成一個獨立的公司集中在OncoSIGNal途徑活性分析技術。投資者包括Casdin資本,生命科學天使,金鍾柏資本和布拉班特發展機構。飛利浦擁有新公司的少數股權。InnoSIGN獨占鼇頭OncoSIGNal mRNA-based測試測量的活動在癌症和免疫細胞信號轉導途徑預測病人會如何應對靶向藥物。的OncoSIGNal Research-Use-Only qPCR 7通路測試可用,使研究實驗室常規PCR機器上運行測試結合OncoSIGNal基於雲的數據分析軟件。投資使InnoSIGN實現其雄心勃勃的發展計劃利用先發優勢完成進一步的臨床驗證研究和在美國市場推出。InnoSIGN inc .)美國公司將保持其領先的研發中心位於高科技園區在埃因霍溫,荷蘭。“我激動的從這個強大的財團投資和讚助美國和荷蘭的投資者,”Paul van de說,InnoSIGN的首席執行官和創始人之一。 “This funding round will enable us to demonstrate the added value of OncoSIGNal compared to standard technologies for the better understanding of cell behavior, which is highly relevant to physicians when selecting the optimal personalized therapy for cancer patients.” “As the limitations of DNA sequencing and protein analysis have become clear during the last years, we believe InnoSIGN’s proprietary mRNA-based signaling pathway tests, database with pathway activity profiles, and advanced analytics software will drive the next breakthroughs in precision medicine, initially in oncology, and then in other autoimmune and infectious disease," said Allan May, chair of Life Science Angels and investor. OncoSIGNal was developed by scientists at Philips Research as a breakthrough technology for quantifying cell signaling pathway activity. Powerful proprietary software normalizes and translates mRNA levels transcribed from a suite of selected genes into activity scores of the relevant signal transduction pathways. OncoSIGNal utilizes its extensive database to gain insight into the signaling pathway profiles of the different cancer and immune cells leading to deep understanding of the mechanisms of the disease and potentially new therapy options. “We are happy to be partnering with this consortium. InnoSIGN, as a stand-alone company, will be able to accelerate the development of OncoSIGNal tests which have the potential to make oncology diagnostics more efficient and precise, leading to better health outcomes,” says Henk van Houten, CTO and Head of Research of Philips. About InnoSIGN InnoSIGN commercializes its proprietary mRNA-based OncoSIGNal pathway activity profiling technology, revolutionizing precision medicine by obtaining more insight into the mechanisms of disease. OncoSIGNal is available for Research-Use-Only offered as qPCR tests for decentralized use and via its service testing facility in The Netherlands. InnoSIGN utilizes its extensive database with more than 100,000 pathway activity profiles to support diagnostics and drug development. For more information please contact Gwen Sülter at oncosignal@innosignbio.com